Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

20

Revenue 2017

Triumeq

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Triumeq was produced by GlaxoSmithKline.

Shingrix lifts GSK in Q1, but two more vaccines are culled

Shingrix lifts GSK in Q1, but two more vaccines are culled

The bulk of GSK’s HIV sales come from its dolutegravir-based combination products Tivicay and Triumeq, but greater competition in the market from arch-rival Gilead Sciences with new products ... That was particularly apparent for three-drug combo

Dovato approval key for Glaxo in HIV treatment

Dovato approval key for Glaxo in HIV treatment those who would otherwise be precluded from receiving [ViiV's] Triumeq (abacavir/dolutegravir/lamivudine) due to abacavir hypersensitivity.”.

MSD claims EU approval for two HIV products

MSD claims EU approval for two HIV products In the US, Merck has priced Delstrigo at $70 per day, at the low end of rivals such as Gilead’s Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) and ViiV’s Triumeq

GSK’s says depot HIV injection works over three years

GSK’s says depot HIV injection works over three years FLAIR is looking at monthly dosing in treatment-naïve patients who have their virus levels controlled initially using ViiV’s three-drug Triumeq (abacavir/dolutegravir/lamivudine) product.

ViiV chalks up another win for two-drug HIV regimen

ViiV chalks up another win for two-drug HIV regimen few years due to the success of drugs like oral integrase inhibitor Tivicay (dolutegravir) and triple regimen Triumeq (dolutegravir/lamivudine/abacavir).

1 2 3 4 5 6 7 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics